LIVECAST Markets Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics News Archive Account

Home News ArchiveFreeport-McMoRan Announces Availability of Third-Quarter and Nine-Month 2026 Results Release

Live News EQUITY FLASH M impact Oct 27, 2026, 12:08 PM UTC

Freeport-McMoRan Announces Availability of Third-Quarter and Nine-Month 2026 Results Release

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

FCX

Related stories

HSBC Reports Third-Quarter Results, Authorizes $1 Billion Buyback HSBC said third-quarter pre-tax profit rose 32% year over year to $9.60 billion and announced a new $1 billion U.S. stock buyback authorization. M impact | EQUITY | Oct 27, 2026, 01:56 PM UTC JetBlue Shares Rally More Than 12% in Early Trade JetBlue shares rose more than 12% in early trading Tuesday as the airline sought to ease concerns about its financial position despite a wider-than-expected quarterly loss. M impact | EQUITY | Oct 27, 2026, 01:56 PM UTC HCA Tops Quarterly Results as Medicaid Payments Offset Uninsured Care Hit HCA reported quarterly results that topped expectations, with Medicaid payments offsetting the impact of uninsured care. M impact | EQUITY | Oct 27, 2026, 01:55 PM UTC Meituan issues dim sum bonds Meituan issued dim sum bonds after order demand exceeded the reported threshold. M impact | EQUITY | Oct 27, 2026, 01:52 PM UTC Meituan Launches Dim Sum Bond Offering Meituan launched a dim sum bond offering, with subscriptions exceeding the stated issue size. M impact | EQUITY | Oct 27, 2026, 01:52 PM UTC Novartis Stops Late-Stage Trial of Remibrutinib for Lack of Efficacy Novartis said it stopped a late-stage trial of remibrutinib in a rare neuromuscular disease due to lack of efficacy. M impact | EQUITY | Oct 27, 2026, 01:51 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Macro
Politics
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.